Results overview: Found 4 records in 0.02 seconds.
Articles, 4 records found
Articles 4 records found  
1.
8 p, 390.2 KB Utilisation and Off-Label Prescriptions of Respiratory Drugs in Children / Schmiedl, Sven (Philipp Klee-Institute for Clinical Pharmacology, HELIOS Clinic Wuppertal, Germany) ; Fischer, Rainald (Pneumologische Praxis München-Pasing, Munich, Germany) ; Ibáñez, Luisa (Universitat Autònoma de Barcelona. Departament de Farmacologia, de Terapèutica i de Toxicologia) ; Fortuny, Joan (Novartis Farmacéutica (Barcelona, Catalunya)) ; Klungel, Olaf H. (Utrecht University, the Netherlands) ; Reynolds, Robert (Epidemiology, Pfizer, New York, United States of America) ; Gerlach, Roman (National Association of Statutory Health Insurance Physicians of Bavaria, Munich, Germany) ; Tauscher, Martin (National Association of Statutory Health Insurance Physicians of Bavaria, Germany) ; Thürmann, Petra (Philipp Klee-Institute for Clinical Pharmacology, HELIOS Clinic Wuppertal, Wuppertal, Germany) ; Hasford, Joerg (Institute for Medical Information Sciences, Biometry, and Epidemiology, Ludwig-Maximilians-Universitaet, Munich, Germany) ; Rottenkolber, Marietta (Institute for Medical Information Sciences, Biometry, and Epidemiology, Ludwig-Maximilians-Universitaet, Munich, Germany)
Respiratory drugs are widely used in children to treat labeled and non-labeled indications but only some data are available quantifying comprehensively off-label usage. Thus, we aim to analyse drug utilisation and off-label prescribing of respiratory drugs focusing on age- and indication-related off-label use. [...]
2014 - 10.1371/journal.pone.0105110
PloS one, Vol. 9 (september 2014)  
2.
16 p, 1.2 MB Incidence of direct oral anticoagulant use in patients with nonvalvular atrial fibrillation and characteristics of users in 6 European countries (2008-2015) : A cross-national drug utilization study / Ibáñez, Luisa (Universitat Autònoma de Barcelona) ; Sabaté, Mònica (Universitat Autònoma de Barcelona) ; Vidal Guitart, Xavier (Universitat Autònoma de Barcelona) ; Ballarín, Elena (Hospital Universitari Vall d'Hebron) ; Rottenkolber, Marietta (Klinikum der Universität München) ; Schmiedl, Sven (Helios University Hospital Wuppertal) ; Heeke, Andreas (AOK NORDWEST) ; Huerta, Consuelo (Agencia Española de Medicamentos y Productos Sanitarios) ; Martin Merino, Elisa (Agencia Española de Medicamentos y Productos Sanitarios) ; Montero, Dolores (Agencia Española de Medicamentos y Productos Sanitarios) ; Leon-Muñoz, Luz María (Agencia Española de Medicamentos y Productos Sanitarios) ; Gasse, Christiane (Aarhus University) ; Moore, Nicholas (INSERM CIC1401, Université de Bordeaux) ; Droz, Cécile (INSERM CIC1401, Université de Bordeaux) ; Lassalle, Régis (INSERM CIC1401, Université de Bordeaux) ; Aakjær, Mia (University of Copenhagen) ; Andersen, Morten (University of Copenhagen) ; De Bruin, Marie Louise (University of Copenhagen) ; Groenwold, Rolf (Leiden University Medical Center) ; van den Ham, Hendrika A. (Universiteit Utrecht, David de Wiedgebouw) ; Souverein, Patrick (Universiteit Utrecht, David de Wiedgebouw) ; Klungel, Olaf (University Medical Center Utrecht) ; Gardarsdottir, Helga (University of Iceland) ; Universitat Autònoma de Barcelona ; Hospital Universitari Vall d'Hebron
To estimate the incidence of direct oral anticoagulant drug (DOAC) use in patients with nonvalvular atrial fibrillation and to describe user and treatment characteristics in 8 European healthcare databases representing 6 European countries. [...]
2019 - 10.1111/bcp.14071
British Journal of Clinical Pharmacology, Vol. 85 (september 2019) , p. 2524-2539  
3.
9 p, 3.3 MB Sales of macrolides, lincosamides, streptogramins, and amoxicillin/clavulanate in the in- and outpatient setting in 10 European countries, 2007-2010 / Ferrer, Pili (Fundació Institut Català de Farmacologia) ; Sabaté, Mònica (Universitat Autònoma de Barcelona. Departament de Farmacologia, de Terapèutica i de Toxicologia) ; Ballarín, Elena (Universitat Autònoma de Barcelona. Departament de Farmacologia, de Terapèutica i de Toxicologia) ; Fortuny, Joan (RTI Health Solutions) ; Rottenkolber, Marietta (Diabetes Research Group, Medical Department 4, University Hospital Munich, Campus Innenstadt, Ludwig-Maximilians-Universität, Ziemssenstr 1) ; Schmiedl, Sven (Department of Clinical Pharmacology, School of Medicine, Faculty of Health, Witten-Herdecke University, Alfred Herrhausen-Strasse 50) ; Laporte Rosselló, Joan-Ramón (Universitat Autònoma de Barcelona. Departament de Farmacologia, de Terapèutica i de Toxicologia) ; Ibáñez, Luisa (Universitat Autònoma de Barcelona. Departament de Farmacologia, de Terapèutica i de Toxicologia) ; Fundació Institut Català de Farmacologia
The online version of this article (doi:10. 1186/s40064-015-1398-4) contains supplementary material, which is available to authorized users.
2015 - 10.1186/s40064-015-1398-4
SpringerPlus, Vol. 4 (october 2015)  
4.
10 p, 619.3 KB Prescribing of long-acting beta-2-agonists/inhaled corticosteroids after the SMART trial / Rottenkolber, Marietta (Institute for Medical Information Sciences, Biometry, and Epidemiology, Ludwig-Maximilians-Universitaet) ; Fischer, Rainald (Pneumologische Praxis Muenchen - Pasing, Munich, Germany) ; Ibáñez, Luisa (Universitat Autònoma de Barcelona. Departament de Farmacologia, de Terapèutica i de Toxicologia) ; Fortuny, Joan (Novartis Farmaceutica SA) ; Reynolds, Robert (Pfizer Research & Development, New York, USA) ; Amelio, Justyna (Amgen Ltd, Uxbridge, UK) ; Gerlach, Roman (National Association of Statutory Health Insurance Physicians of Bavaria, Munich, Germany) ; Tauscher, Martin (National Association of Statutory Health Insurance Physicians of Bavaria, Munich, Germany) ; Thürmann, Petra (Philipp Klee-Institute for Clinical Pharmacology, HELIOS Clinic Wuppertal, Wuppertal, Germany) ; Hasford, Joerg (Institute for Medical Information Sciences, Biometry, and Epidemiology, Ludwig-Maximilians-Universitaet) ; Schmiedl, Sven (Philipp Klee-Institute for Clinical Pharmacology, HELIOS Clinic Wuppertal, Wuppertal, Germany)
After the SMART trial evaluating the safety of salmeterol (long-acting beta-2-agonist (LABA)) in asthma patients, regulatory actions were taken to promote a guideline-adherent prescribing of LABA only to patients receiving inhaled corticosteroids (ICS). [...]
2015 - 10.1186/s12890-015-0051-x
BMC Pulmonary Medicine, Vol. 15 (may 2015)  

See also: similar author names
2 Schmiedl, S.
Interested in being notified about new results for this query?
Set up a personal email alert or subscribe to the RSS feed.